BNP Paribas Financial Markets
GEVA

BNP Paribas Financial Markets’s SYNAGEVA BIOPHARMA CORP COM STK (DE) GEVA Stock Holding History

BNP Paribas Financial Markets’s Portfolio GEVA Stock Details GEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-476
Closed -$46.4K – 3732
2015
Q1 		$46.4K Buy
+476
New +$50.4K ﹤0.01% 1960
2014
Q4 		– Sell
-1,290
Closed -$88.7K – 4020
2014
Q3 		$88.7K Buy
1,290
+1,226
+1,916% +$87.8K ﹤0.01% 2260
2014
Q2 		$6.71K Buy
+64
New +$5.45K ﹤0.01% 2459
2014
Q1 		– Sell
-248
Closed -$16.1K – 4149
2013
Q4 		$16.1K Sell
248
-4,461
-95% -$265K ﹤0.01% 2353
2013
Q3 		$299K Sell
4,709
-1,656
-26% -$81.5K ﹤0.01% 1925
2013
Q2 		$267K Buy
+6,365
New +$290K ﹤0.01% 2097

BNP Paribas Financial Markets's GEVA Position: Q2 2015 in Review

BNP Paribas Financial Markets sold out of SYNAGEVA BIOPHARMA CORP COM STK (DE) (GEVA) in Q2 2015, closing a stake of 476 shares — an estimated $46.4K sold.

BNP Paribas Financial Markets first reported a position in GEVA in Q2 2013 and held it in 6 quarters. The position peaked at $299K in Q3 2013. 0 funds tracked by Wall St. Rank hold GEVA as of Q2 2015.

  • BNP Paribas Financial Markets reported no remaining SYNAGEVA BIOPHARMA CORP COM STK (DE) position as of Q2 2015 after selling out during the quarter.
  • BNP Paribas Financial Markets sold 476 SYNAGEVA BIOPHARMA CORP COM STK (DE) shares in Q2 2015, an estimated $46.4K.
  • BNP Paribas Financial Markets first reported a position in SYNAGEVA BIOPHARMA CORP COM STK (DE) in Q2 2013 and held it in 6 quarters.
  • BNP Paribas Financial Markets's SYNAGEVA BIOPHARMA CORP COM STK (DE) position peaked at $299K in Q3 2013.
  • 0 funds tracked by Wall St. Rank held SYNAGEVA BIOPHARMA CORP COM STK (DE) as of Q2 2015.

Based on BNP Paribas Financial Markets's 13F filing for Q2 2015, filed 14 Aug 2015.